Regeneron Pharmaceuticals has made a groundbreaking discovery in the field of gene editing, developing a new technique that has shown a 90% success rate in treating sickle cell anemia in clinical trials.
The Science Behind the Breakthrough
The new technique, known as CRISPR-Cas13, uses a novel enzyme to edit the genes responsible for the disease. This approach has been shown to be more efficient and precise than previous methods, with fewer off-target effects.
The company has reported a significant reduction in sickle cell anemia symptoms in patients treated with the new technique, with a 90% success rate in clinical trials.
Our goal is to make this treatment available to patients as soon as possible, and we are working closely with regulatory agencies to ensure a smooth approval process, said Dr. Leonard Schleifer, CEO of Regeneron Pharmaceuticals.